In a landmark development for the HIV therapeutic landscape, pharmaceutical giants Gilead Sciences and Merck have unveiled promising Phase 3 data for a novel, once-weekly oral treatment regimen. The investigational combination—consisting of Merck’s islatravir and Gilead’s lenacapavir—has successfully maintained virologic suppression in a combined cohort of 1,209 adults living with HIV. Presented at the 26th International AIDS Conference, these findings represent a potential seismic shift in how patients manage a condition that has historically required strict, daily adherence to complex pharmacological protocols.
For the millions of people living with HIV, the prospect of transitioning from a seven-pill-per-week regimen to a single once-weekly tablet offers more than just pharmacological efficacy; it promises a profound improvement in quality of life and treatment adherence.
The Science of Suppression: Understanding the Combination
The investigational regimen pairs 2 mg of islatravir, a next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI) developed by Merck, with 300 mg of Gilead’s lenacapavir, a first-in-class capsid inhibitor.
The efficacy of this combination is rooted in the distinct pharmacokinetic profiles of the two drugs. Islatravir functions by inhibiting HIV-1 replication through multiple mechanisms, effectively stalling the virus’s ability to hijack host cells. When coupled with lenacapavir—which disrupts the HIV capsid, a protein shell essential for the virus’s lifecycle—the duo creates a potent barrier against viral rebound. The unique metabolic stability of these agents allows for a significantly longer half-life compared to the current standard of daily antiretroviral therapy (ART), making a weekly dosage frequency clinically viable.
Chronology: From Concept to Phase 3 Validation
The journey to this milestone has been methodical, spanning several years of rigorous clinical investigation:
- October 2024: Gilead and Merck announced positive Phase 2 data. A study of 104 virologically suppressed adults showed that 94.2% of those on the weekly ISL/LEN regimen maintained suppression at 48 weeks, with no participant experiencing virologic failure. By Week 96, these results were sustained, and no emergent drug resistance was detected.
- April 2026: The FDA granted approval for Merck’s Idvynso (doravirine/islatravir), validating the clinical utility of islatravir as a core component of HIV treatment.
- June 8, 2026: The companies released topline findings from the ISLEND-1 and ISLEND-2 trials, confirming the potential for a once-weekly dosing schedule.
- July 2026: Detailed results from the ISLEND-1 and ISLEND-2 trials were formally presented at the 26th International AIDS Conference, marking the first time the full Phase 3 dataset was subjected to peer-level academic scrutiny.
Supporting Data: The ISLEND Trial Results
The ISLEND trials were designed to test the regimen across diverse clinical environments, ensuring the data would be robust enough for regulatory scrutiny.
ISLEND-1: The Gold Standard
The ISLEND-1 trial utilized a double-blind, randomized design involving 609 participants. The results were striking: zero participants in the weekly ISL/LEN arm experienced HIV-1 RNA levels at or above 50 copies/mL at Week 48. In contrast, 0.3% of the control group—patients remaining on the industry-standard Biktarvy—experienced similar viral levels. Adverse event profiles were balanced, with 13.5% of the ISL/LEN group reporting treatment-related side effects compared to 13.2% in the Biktarvy cohort.
ISLEND-2: Real-World Application
ISLEND-2 took a more pragmatic approach, utilizing an open-label design with 600 participants who switched from a variety of existing multi-drug regimens. Despite the more varied baseline conditions, the efficacy remained comparable. Only 0.3% of the investigational group saw viral rebound, compared to 1.3% of those who continued their baseline therapy. Notably, participants in the ISL/LEN arm reported higher levels of treatment satisfaction and described the regimen as significantly less burdensome than their previous daily therapies.
Clinical Considerations and Potential Challenges
While the efficacy data is overwhelmingly positive, the medical community has raised important clinical considerations regarding the switch from standard-of-care treatments like Biktarvy.
A critical point of discussion centers on Hepatitis B (HBV) coverage. Biktarvy contains tenofovir alafenamide, which provides dual coverage for HIV and HBV. Because the ISL/LEN combination does not contain tenofovir, patients co-infected with Hepatitis B—or those who require HBV prophylaxis—may require additional management strategies. During the Phase 2 trials, one participant acquired Hepatitis B upon switching, highlighting the necessity for robust screening and, where appropriate, vaccination protocols before transitioning patients to this new regimen.
Implications for the HIV Treatment Market
The financial and competitive implications of a successful once-weekly tablet cannot be overstated. Currently, the market is dominated by daily single-tablet regimens, most notably Gilead’s Biktarvy, which generated a staggering $14.3 billion in 2025.
Shifting the Market Dynamic
Gilead’s willingness to disrupt its own market leader (Biktarvy) is a strategic move aimed at long-term dominance. As patients and providers increasingly prioritize convenience and reduced treatment burden, the shift toward long-acting and less-frequent dosing is inevitable. By advancing both the weekly oral ISL/LEN regimen and other projects like the bictegravir/lenacapavir combination, Gilead is effectively building a "defense in depth" strategy against both generic competition and the rising popularity of injectable therapies.
The Rise of Injectables
The primary competition for this new oral regimen comes from the injectable space. ViiV Healthcare’s Cabenuva—an injectable administered every one or two months—has seen massive adoption, with a 42% increase in revenue in 2025. While injectables offer the ultimate "set and forget" convenience, they require clinic visits. The ISL/LEN combination offers a "middle ground": the convenience of reduced dosing frequency without the requirement for frequent, facility-based administration. This home-based, weekly oral option may appeal to patients who desire simplicity but prefer to maintain control over their own medication schedule.
Future Outlook: A New Standard of Care
The data from ISLEND-1 and ISLEND-2 suggest that we are on the precipice of a new era in HIV management. If approved, the ISL/LEN regimen will not only provide a high barrier to resistance and excellent virologic control, but it will also represent a fundamental shift in the psychological experience of living with HIV.
The transition from daily adherence to a weekly ritual could reduce the stigma associated with chronic treatment and improve long-term outcomes by minimizing the "pill fatigue" that can sometimes lead to inconsistent adherence. As Gilead and Merck prepare their regulatory filings, the global HIV community is watching closely, hopeful that this collaboration will deliver a tool that makes the daily management of HIV a thing of the past.
By combining the pharmacological strengths of islatravir and lenacapavir, the companies are not just seeking to maintain viral suppression—they are seeking to liberate patients from the daily reminder of their condition. As the regulatory process unfolds over the coming months, the focus will shift to how healthcare systems and insurance providers integrate this weekly innovation into standard practice, potentially setting a new benchmark for chronic disease management in the 21st century.
About the Author
